Publications

Glitza Oliva IC, Ferguson SD, Bassett R Jr, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MA. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 Mar 30. doi: 10.1038/s41591-022-02170-x. Epub ahead of print. PMID: 36997799.

Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP,Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M,Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R,Faria S, Nagarajan P, Amaria RN. Neoadjuvant checkpoint inhibitor immunotherapy forresectable mucosal melanoma. Frontiers in oncology. 2022;12:1001150. PubMed PMID:36324592; PubMed Central PMCID: PMC9618687; DOI: 10.3389/fonc.2022.1001150.

Karasarides M, Cogdill AP, Robbins PB, Bowden M, Burton EM, Butterfield LH, Cesano A,Hammer C, Haymaker CL, Horak CE, McGee HM, Monette A, Rudqvist NP, Spencer CN, SweisRF, Vincent BG, Wennerberg E, Yuan J, Zappasodi R, Lucey VMH, Wells DK, LaVallee T.Hallmarks of Resistance to Immune-Checkpoint Inhibitors. Cancer immunology research.2022 April 1;10(4):372-383. PubMed PMID: 35362046; PubMed Central PMCID:PMC9381103; DOI: 10.1158/2326-6066.CIR-20-0586.

Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E,Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T,Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A,Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J,Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks ofinflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Naturecommunications. 2022 April 12;13(1):1970. PubMed PMID: 35413951; PubMed CentralPMCID: PMC9005525; DOI: 10.1038/s41467-022-29539-3.

Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mulé JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC,Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, HaymakerC, Beroukhim R, Bernatchez C. Genomic Correlates of Outcome in Tumor-InfiltratingLymphocyte Therapy for Metastatic Melanoma. Clinical cancer research : an official journal ofthe American Association for Cancer Research. 2022 May 2;28(9):1911-1924. PubMed PMID:35190823; PubMed Central PMCID: PMC9064946; DOI: 10.1158/1078-0432.CCR-21-1060.

Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C,Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A,Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS,Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP,Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity andpromotes tumor immunity. Cancer cell. 2022 May 9;40(5):509-523.e6. PubMed PMID:35537412; PubMed Central PMCID: PMC9221568; DOI: 10.1016/j.ccell.2022.04.004.

Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med. 2022. Epub 2022/02/01. doi: 10.1002/sim.9337. PubMed PMID: 35098585.

Koc S, Lloyd MW, Grover JW, Xiao N, Seepo S, Subramanian SL, Ray M, Frech C, DiGiovannaJ, Webster P, Neuhauser S, Srivastava A, Woo XY, Sanderson BJ, White B, Lott P, DobroleckiLE, Dowst H, Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, PanCX, Chen MS, Carvajal-Carmona L, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S,Herlyn M, Davies MA, Roth J, Meric-Bernstam F, Robinson PN, Bult CJ, Davis-Dusenbery B,Dean DA 2nd, Chuang JH. PDXNet portal: patient-derived Xenograft model, data, workflowand tool discovery. NAR cancer. 2022 June;4(2):zcac014. PubMed PMID: 35475145; PubMedCentral PMCID: PMC9026194; DOI: 10.1093/narcan/zcac014.

Hickman A, Koetsier J, Kurtanich T, Nielsen MC, Winn G, Wang Y, Bentebibel SE, Shi L, PuntS, Williams L, Haymaker C, Chesson CB, Fa'ak F, Dominguez AL, Jones R, Kuiatse I, CaivanoAR, Khounlo S, Warier ND, Marathi U, Market RV, Biediger RJ, Craft JW Jr, Hwu P, DaviesMA, Woodside DG, Vanderslice P, Diab A, Overwijk WW, Hailemichael Y. LFA-1 activationenriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade.The Journal of clinical investigation. 2022 July 1;132(13). PubMed PMID: 35552271; PubMedCentral PMCID: PMC9246385; DOI: 10.1172/JCI154152.

Biermann J, Melms JC, Amin AD, Wang Y, Caprio LA, Karz A, Tagore S, Barrera I, Ibarra-Arellano MA, Andreatta M, Fullerton BT, Gretarsson KH, Sahu V, Mangipudy VS, Nguyen TTT,Nair A, Rogava M, Ho P, Koch PD, Banu M, Humala N, Mahajan A, Walsh ZH, Shah SB,Vaccaro DH, Caldwell B, Mu M, Wünnemann F, Chazotte M, Berhe S, Luoma AM, Driver J,Ingham M, Khan SA, Rapisuwon S, Slingluff CL Jr, Eigentler T, Röcken M, Carvajal R, AtkinsMB, Davies MA, Agustinus A, Bakhoum SF, Azizi E, Siegelin M, Lu C, Carmona SJ, HibshooshH, Ribas A, Canoll P, Bruce JN, Bi WL, Agrawal P, Schapiro D, Hernando E, Macosko EZ, ChenF, Schwartz GK, Izar B. Dissecting the treatment-naive ecosystem of human melanoma brainmetastasis. Cell. 2022 July 7;185(14):2591-2608.e30. PubMed PMID: 35803246; PubMedCentral PMCID: PMC9677434; DOI: 10.1016/j.cell.2022.06.007.

Andrews MC, Oba J, Wu CJ, Zhu H, Karpinets T, Creasy CA, Forget MA, Yu X, Song X, Mao X,Robertson AG, Romano G, Li P, Burton EM, Lu Y, Sloane RS, Wani KM, Rai K, Lazar AJ,Haydu LE, Bustos MA, Shen J, Chen Y, Morgan MB, Wargo JA, Kwong LN, Haymaker CL,Grimm EA, Hwu P, Hoon DSB, Zhang J, Gershenwald JE, Davies MA, Futreal PA, BernatchezC, Woodman SE. Multi-modal molecular programs regulate melanoma cell state. Naturecommunications. 2022 July 9;13(1):4000. PubMed PMID: 35810190; PubMed Central PMCID:PMC9271073; DOI: 10.1038/s41467-022-31510-1.

Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G,Bracht JWP, Gerlinger M, Shinozaki E, Yoshino T, Kotani D, Fangusaro JR, Gautschi O,Mazieres J, Sosman JA, Kopetz S, Subbiah V, Davies MA, Groover AL, Sullivan RJ, FlahertyKT, Johnson DB, Benedetti A, Cescon DW, Spreafico A, Zogopoulos G, Rose AAN. ClinicalActivity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600BRAF-Mutant Tumors. JCO precision oncology. 2022 August;6:e2200107. PubMed PMID:35977349; DOI: 10.1200/PO.22.00107.

Stejerean-Todoran I, Gimotty PA, Watters A, Brafford P, Krepler C, Godok T, Li H, Bonilla DelRio Z, Zieseniss A, Katschinski DM, Sertel SM, Rizzoli SO, Garman B, Nathanson KL, Xu X,Chen Q, Oswald JH, Lotem M, Mills GB, Davies MA, Schön MP, Bogeski I, Herlyn M, Vultur A.A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells. Neurooncology.2022 September 2. PubMed PMID: 36054930; DOI: 10.1093/neuonc/noac212.

Aizer AA, Lamba N, Ahluwalia MS, Aldape K, Boire A, Brastianos PK, Brown PD, Camidge DR,Chiang VL, Davies MA, Hu LS, Huang RY, Kaufmann T, Kumthekar P, Lam K, Lee EQ, Lin NU,Mehta M, Parsons M, Reardon DA, Sheehan J, Soffietti R, Tawbi H, Weller M, Wen PY. Brainmetastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-oncology. 2022 October 3;24(10):1613-1646. PubMed PMID:35762249; PubMed Central PMCID: PMC9527527; DOI: 10.1093/neuonc/noac118.

Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F,Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, GoepfertRP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK,Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, LucciA, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Neoadjuvantrelatlimab and nivolumab in resectable melanoma. Nature. 2022 November;611(7934):155-160. PubMed PMID: 36289334; PubMed Central PMCID: PMC9607737; DOI:10.1038/s41586-022-05368-8.

Luo L, Shen R, Arora A, Orlow I, Busam KJ, Lezcano C, Lee TK, Hernando E, Gorlov I, AmosC, Ernstoff MS, Seshan VE, Cust AE, Wilmott J, Scolyer RA, Mann G, Nagore E, Funchain P,Ko J, Ngo P, Edmiston SN, Conway K, Googe PB, Ollila D, Lee JE, Fang S, Rees JR,Thompson CL, Gerstenblith M, Bosenberg M, Gould Rothberg B, Osman I, Saenger Y,Reynolds AZ, Schwartz M, Boyce T, Holmen S, Brunsgaard E, Bogner P, Kuan PF, Wiggins C,Thomas NE, Begg CB, Berwick M. Landscape of mutations in early stage primary cutaneousmelanoma: An InterMEL study. Pigment cell & melanoma research. 2022November;35(6):605-612. PubMed PMID: 35876628; PubMed Central PMCID: PMC9640183;DOI: 10.1111/pcmr.13058.

Tu H, McQuade JL, Davies MA, Huang M, Xie K, Ye Y, Chow WH, Rodriguez A, Wu X. Bodymass index and survival after cancer diagnosis: A pan-cancer cohort study of 114 430patients with cancer. Innovation (Cambridge (Mass.)). 2022 November 8;3(6):100344.PubMed PMID: 36353671; PubMed Central PMCID: PMC9638833; DOI:10.1016/j.xinn.2022.100344.

Zhou Z, Chen MM, Luo Y, Mojumdar K, Peng X, Chen H, Kumar SV, Akbani R, Lu Y, Liang H.Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy inmelanoma. Cancer cell. 2022 November 14;40(11):1324-1340.e8. PubMed PMID: 36332624;PubMed Central PMCID: PMC9669221; DOI: 10.1016/j.ccell.2022.10.012.

Hou J, Liang S, Xu C, Wei Y, Wang Y, Tan Y, Sahni N, McGrail DJ, Bernatchez C, Davies M, LiY, Chen R, Yi SS, Chen Y, Yee C, Chen K, Peng W. Single-cell CRISPR immune screens revealimmunological roles of tumor intrinsic factors. NAR cancer. 2022 December;4(4):zcac038.PubMed PMID: 36518525; PubMed Central PMCID: PMC9732527; DOI:10.1093/narcan/zcac038.

Hasanov M, Milton DR, Bea Davies A, Sirmans E, Saberian C, Posada EL, Opusunju S,Gershenwald JE, Torres-Cabala CA, Burton EM, Colen R, Huse JT, Glitza Oliva IC, Chung C,McAleer MF, McGovern SL, Yeboa DN, Kim BYS, Prabhu SS, McCutcheon IE, Weinberg J,Lang FF, Tawbi HA, Li J, Haydu LE, Davies MA, Ferguson SD. Changes In Outcomes AndFactors Associated With Survival In Melanoma Patients With Brain Metastases. Neurooncology.2022 December 13. PubMed PMID: 36510640; DOI: 10.1093/neuonc/noac251.

Chattopadhyay C, Bhattacharya R, Roszik J, Khan FS, Wells GA, Villanueva H, Qin Y,Bhattacharya R, Patel SP, Grimm EA. Targeting IRS-1/2 in Uveal Melanoma Inhibits In VitroCell Growth, Survival and Migration, and In Vivo Tumor Growth. Cancers. 2022 December19;14(24). PubMed PMID: 36551732; PubMed Central PMCID: PMC9777326; DOI:10.3390/cancers14246247.

Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, LeeH, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA,Kirkwood JM, Long GV, Davies MA. Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-MutantMelanoma Brain Metastases. Clinical cancer research : an official journal of the AmericanAssociation for Cancer Research. 2023 February 1;29(3):521-531. PubMed PMID: 36477181;PubMed Central PMCID: PMC9898142; DOI: 10.1158/1078-0432.CCR-22-2581.

Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Park EM, BabcockRL, Chrisikos TT, Kahn LM, Dyevoich AM, Pineda JE, Wong MC, Mishra AK, Cass SH, CogdillAP, Johnson DH, Johnson SB, Wani K, Ledesma DA, Hudgens CW, Wang J, Wadud Khan MA,Peterson CB, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, TetzlaffMT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A,Wargo JA, Watowich SS. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloidinfiltration. The Journal of experimental medicine. 2023 February 6;220(2). PubMed PMID:36367776; PubMed Central PMCID: PMC9664499; DOI: 10.1084/jem.20221333.

Chagani S, De Macedo MP, Carapeto F, Wang F, Marzese DM, Wani K, Haydu LE, Peng W,Ong GT, Warren SE, Beechem JM, Hoon DSB, Mills GB, Tetzlaff MT, Lazar AJ, Kwong LN,Davies MA. MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY INMELANOMA. The Journal of investigative dermatology. 2023 March 3. PubMed PMID:36871660; DOI: 10.1016/j.jid.2023.01.034.

Saberian C, Davies MA. Re-thinking therapeutic development for CNS metastatic disease. Exp Dermatol. 2022;31(1):74-81. Epub 2021/06/22. doi: 10.1111/exd.14413. PubMed PMID: 34152638.

Fukuda Y, Bustos MA, Cho S-N, Roszik J, Ryu S, Lopez VM, Burks JK, Lee JE, Grimm EA, Hoon DSB, Ekmekcioglu S. Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death & Disease. 2022;13(2):117. doi: 10.1038/s41419-022-04552-y.

Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mule JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC, Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, Haymaker C, Beroukhim R, Bernatchez C. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res. 2022. Epub 2022/02/23. doi: 10.1158/1078-0432.Ccr-21-1060. PubMed PMID: 35190823.

Zhou Y, Lin R, Lee JJ. The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials. Pharm Stat. 2021;20(6):1183-99. Epub 2021/05/20. doi: 10.1002/pst.2139. PubMed PMID: 34008317.

Zhou Y, Lin R, Kuo YW, Lee JJ, Yuan Y. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. JCO Clin Cancer Inform. 2021;5:91-101. Epub 2021/01/14. doi: 10.1200/cci.20.00122. PubMed PMID: 33439726; PMCID: PMC8462603.

Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov. 2021;11(6):1368-97. Epub 2021/04/04. doi: 10.1158/2159-8290.Cd-20-1209. PubMed PMID: 33811048; PMCID: PMC8178168.

White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021;10(1):1992880. Epub 2021/11/16. doi: 10.1080/2162402x.2021.1992880. PubMed PMID: 34777916; PMCID: PMC8583008.

Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021;374(6575):1632-40. Epub 2021/12/24. doi: 10.1126/science.aaz7015. PubMed PMID: 34941392; PMCID: PMC8970537.

Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, Glover MS, Simien R, Diab A, Hwu P, Carter BW, Patel SP. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol. 2021;39(6):599-607. Epub 2020/10/31. doi: 10.1200/jco.20.00605. PubMed PMID: 33125309; PMCID: PMC8257877.

Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, Saw RPM, Xu X, Karakousis GC, Ascierto PA, Spillane AJ, van Akkooi ACJ, Davies MA, Mitchell TC, Tawbi HA, Scolyer RA, Wargo JA, Blank CU, Long GV. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27(2):301-9. Epub 2021/02/10. doi: 10.1038/s41591-020-01188-3. PubMed PMID: 33558722.

Mejbel HA, Torres-Cabala CA, Milton DR, Ivan D, Nagarajan P, Curry JL, Ciurea AM, Rubin AI, Hwu WJ, Prieto VG, Aung PP. Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma. Arch Pathol Lab Med. 2021;145(8):943-52. Epub 2020/12/09. doi: 10.5858/arpa.2020-0308-OA. PubMed PMID: 33290520.

Mei Y, Chen MM, Liang H, Ma L. A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma. Commun Biol. 2021;4(1):383. Epub 2021/03/24. doi: 10.1038/s42003-021-01911-x. PubMed PMID: 33753855; PMCID: PMC7985195.

Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111. Epub 2021/06/03. doi: 10.1186/s12874-021-01308-8. PubMed PMID: 34074267; PMCID: PMC8168323.

Lin R, Yang Z, Yuan Y, Yin G. Sample size re-estimation in adaptive enrichment design. Contemp Clin Trials. 2021;100:106216. Epub 2020/11/28. doi: 10.1016/j.cct.2020.106216. PubMed PMID: 33246098.

Lin R, Thall PF, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Anal. 2021;16(1):179-202. Epub 2021/07/17. doi: 10.1214/20-ba1205. PubMed PMID: 34267857; PMCID: PMC8277108.

Lin R, Chan KG, Shi H. A unified Bayesian framework for exact inference of area under the receiver operating characteristic curve. Stat Methods Med Res. 2021;30(10):2269-87. Epub 2021/09/02. doi: 10.1177/09622802211037070. PubMed PMID: 34468238.

Li J, Chen H, Wang Y, Chen MM, Liang H. Next-Generation Analytics for Omics Data. Cancer Cell. 2021;39(1):3-6. Epub 2020/09/26. doi: 10.1016/j.ccell.2020.09.002. PubMed PMID: 32976776; PMCID: PMC8336660.

Hou J, Wang Y, Shi L, Chen Y, Xu C, Saeedi A, Pan K, Bohat R, Egan NA, McKenzie JA, Mbofung RM, Williams LJ, Yang Z, Sun M, Liang X, Rodon Ahnert J, Varadarajan N, Yee C, Chen Y, Hwu P, Peng W. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer. 2021;9(2). Epub 2021/02/17. doi: 10.1136/jitc-2020-001819. PubMed PMID: 33589527; PMCID: PMC7887353.

Haymaker C, Johnson DH, Murthy R, Bentebibel SE, Uemura MI, Hudgens CW, Safa H, James M, Andtbacka RHI, Johnson DB, Shaheen M, Davies MA, Rahimian S, Chunduru SK, Milton DR, Tetzlaff MT, Overwijk WW, Hwu P, Gabrail N, Agrawal S, Doolittle G, Puzanov I, Markowitz J, Bernatchez C, Diab A. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. Cancer Discov. 2021;11(8):1996-2013. Epub 2021/03/13. doi: 10.1158/2159-8290.Cd-20-1546. PubMed PMID: 33707233; PMCID: PMC8544022.

Ding Z, Ogata D, Roszik J, Qin Y, Kim S, Tetzlaff M, Lazar AJ, Davies MA, Ekmekcioglu S, Grimm EA. iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Frontiers in Oncology. 2021;11:141.

Cho WC, Wang WL, Milton DR, Ingram DR, Nagarajan P, Curry JL, Ivan D, Lazar AJ, Hwu WJ, Prieto VG, Torres-Cabala CA, Aung PP. Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. Arch Pathol Lab Med. 2021;145(7):842-50. Epub 2020/10/15. doi: 10.5858/arpa.2020-0330-OA. PubMed PMID: 33053175.

Cho WC, Wang WL, Milton DR, Ingram DR, Nagarajan P, Curry JL, Ivan D, Lazar AJ, Hwu WJ, Prieto VG, Torres-Cabala CA, Aung PP. Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. Arch Pathol Lab Med. 2021;145(7):842-50. Epub 2020/10/15. doi: 10.5858/arpa.2020-0330-OA. PubMed PMID: 33053175.

Cheng LY, Haydu LE, Song P, Nie J, Tetzlaff MT, Kwong LN, Gershenwald JE, Davies MA, Zhang DY. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Scientific Reports. 2021;11(1):9043. doi: 10.1038/s41598-021-88391-5.

Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021;27(10):2678-97. Epub 2021/01/09. doi: 10.1158/1078-0432.Ccr-20-4092. PubMed PMID: 33414132; PMCID: PMC8127340.

Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021;27(8):1432-41. Epub 2021/07/10. doi: 10.1038/s41591-021-01406-6. PubMed PMID: 34239137.

Zhao W, Li J, Chen MM, Luo Y, Ju Z, Nesser NK, Johnson-Camacho K, Boniface CT, Lawrence Y, Pande NT, Davies MA, Herlyn M, Muranen T, Zervantonakis IK, von Euw E, Schultz A, Kumar SV, Korkut A, Spellman PT, Akbani R, Slamon DJ, Gray JW, Brugge JS, Lu Y, Mills GB, Liang H. Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell. 2020;38(6):829-43.e4. Epub 2020/11/07. doi: 10.1016/j.ccell.2020.10.008. PubMed PMID: 33157050; PMCID: PMC7738392.

Xu G, Zhu H, Lee JJ. Borrowing Strength and Borrowing Index for Bayesian Hierarchical Models. Comput Stat Data Anal. 2020;144. Epub 2020/04/29. doi: 10.1016/j.csda.2019.106901. PubMed PMID: 32341613; PMCID: PMC7185234.

Ogata D, Roszik J, Oba J, Kim SH, Bassett RL, Jr., Haydu LE, Tanese K, Grimm EA, Ekmekcioglu S. The Expression of CD74-Regulated Inflammatory Markers in Stage IV Melanoma: Risk of CNS Metastasis and Patient Survival. Cancers (Basel). 2020;12(12). Epub 2020/12/18. doi: 10.3390/cancers12123754. PubMed PMID: 33327409; PMCID: PMC7764866.

Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Jr., Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba, II, Heymach JV, Peng W, Cascone T. (18)F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020;69(8):1519-34. Epub 2020/04/18. doi: 10.1007/s00262-020-02560-5. PubMed PMID: 32300858; PMCID: PMC7997043.

Lo SN, Ma J, Scolyer RA, Haydu LE, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Ch'ng S, Mann GJ, Gershenwald JE, Thompson JF, Varey AHR. Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol. 2020;38(24):2719-27. Epub 2020/06/13. doi: 10.1200/jco.19.02362. PubMed PMID: 32530761; PMCID: PMC7430218.

Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing A. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel). 2020;12(8). Epub 2020/08/23. doi: 10.3390/cancers12082307. PubMed PMID: 32824391; PMCID: PMC7465458.

Glitza Oliva IC, Tawbi HA. "Liquid Gold" - The unTAPped Potential of Cerebrospinal Fluid Analysis? Clin Cancer Res. 2020;26(9):2083-4. Epub 2020/03/07. doi: 10.1158/1078-0432.Ccr-20-0173. PubMed PMID: 32139404.

Fischer GM, Carapeto FCL, Joon AY, Haydu LE, Chen H, Wang F, Van Arnam JS, McQuade JL, Wani K, Kirkwood JM, Thompson JF, Tetzlaff MT, Lazar AJ, Tawbi HA, Gershenwald JE, Scolyer RA, Long GV, Davies MA. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020;9(22):8650-61. Epub 2020/10/06. doi: 10.1002/cam4.3474. PubMed PMID: 33016647; PMCID: PMC7666738.

Davies MA. Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response? J Clin Oncol. 2020;38(15):1645-7. Epub 2020/02/26. doi: 10.1200/jco.20.00136. PubMed PMID: 32097093; PMCID: PMC7238487.

Chen H, Liang H. A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer. Cancer Cell. 2020;38(5):701-15.e5. Epub 2020/10/03. doi: 10.1016/j.ccell.2020.08.020. PubMed PMID: 33007258; PMCID: PMC7658066.

Ferguson SD, Bindal S, Bassett RL, Jr., Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol. 2019;142(3):499-509. Epub 2019/03/09. doi: 10.1007/s11060-019-03121-2. PubMed PMID: 30847840.

Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Jr., Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018;3(1):e000283. Epub 2018/02/02. doi: 10.1136/esmoopen-2017-000283. PubMed PMID: 29387478; PMCID: PMC5786950